MTOR and non-small cell lung carcinoma: Furthermore, both in vitro and in vivo models of RET+ NSCLC cell lines demonstrated a strong synergistic effect when non-selective anti-RET TKIs were combined with either CDK 4/6 inhibitors or PI3K/mTOR inhibitors [59].